Table of contents
December 2002 Vol 1 No 12
In This Issue
p927 | doi:10.1038/nrd976
Editorial: The numbers game
p929 | doi:10.1038/nrd983
Research Highlights
Analgesics: Just what we wanted
p931 | doi:10.1038/nrd981
Obesity: Dead end for NPY Y5-receptor antagonists?
p932 | doi:10.1038/nrd969
Antibiotic resistance: Confronting S. aureus muscle
p932 | doi:10.1038/nrd979
Alzheimer's disease: Vaccine revisited
p933 | doi:10.1038/nrd971
Prion diseases: Toxic waste
p934 | doi:10.1038/nrd977
Multiple sclerosis: A new use for statins?
p934 | doi:10.1038/nrd978
Cardiovascular disease: Potential potassium protection
p935 | doi:10.1038/nrd973
In brief
Antibacterial drugs | Protein folding and disease | Adrenoceptor pharmacology
p935 | doi:10.1038/nrd980
Bone diseases: Having the cake and eating it
p936 | doi:10.1038/nrd970
News and Analysis
Patent watch
Accurate speculation is not enough | Madey and the Duke
p936 | doi:10.1038/nrd972
From the analyst's couch
The animal health market
p937 | doi:10.1038/nrd975
Reviews
Blocking NO synthesis: how, where and why?
Patrick Vallance & James Leiper
p939 | doi:10.1038/nrd960
The use and analysis of microarray data
Atul Butte
p951 | doi:10.1038/nrd961
Dual-specificity phosphatases as targets for antineoplastic agents
Michael A. Lyon, Alexander P. Ducruet, Peter Wipf & John S. Lazo
p961 | doi:10.1038/nrd963
Microbicides: a new approach to preventing HIV and other sexually transmitted infections
Alan Stone
p977 | doi:10.1038/nrd959
New therapeutics that antagonize endothelin: promises and frustrations
Giuseppe Remuzzi, Norberto Perico & Ariela Benigni
p986 | doi:10.1038/nrd962
Perspectives
Outlook
Looking backwards: a possible new path for drug discovery in psychopharmacology
Edward Shorter
p1003 | doi:10.1038/nrd964
Opinion
As biotech turns 20...
Henry I. Miller
p1007 | doi:10.1038/nrd965
Careers and Recruitment
Start small, think big — the art of process R&D
Hans-Jürgen Federsel
p1013 | doi:10.1038/nrd974
